Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes

📖 Top 50% JournalJun 4, 2025Medicina clinica

Effectiveness of weekly semaglutide in people with heart failure, obesity, and type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

In a study of 406 patients, 60.6% of those treated with once-weekly semaglutide experienced a primary outcome event related to heart failure.

Patients treated with semaglutide had a significantly greater improvement in heart failure health status compared to those not receiving the treatment.
The mean weight loss in patients taking semaglutide was -12.9±4.2 kg, while control patients lost -2.5±1.1 kg.
A significant decrease in heart failure events was observed in the semaglutide group.
There was also a notable reduction in all-cause hospitalizations among patients receiving semaglutide.

AI simplified

INTRODUCTION AND OBJECTIVES: There is still limited evidence on the role of glucagon-like peptide-1 receptor agonists in heart failure. We analyzed the efficacy in terms of health status, and the change in body weight of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.

PATIENTS AND METHODS: This prospective, real-world study included patients with heart heart failure with preserved ejection fraction, obesity and type 2 diabetes treated with once-weekly 1.00mg semaglutide (Sema-Preserved Group) and patients not treated with glucagon-like peptide-1 receptor agonists (Control-Preserved Group). A 1:1 propensity score matching analysis was performed. The primary outcome was the heart failure status defined as the ≥5 point difference in the Spanish version of the Kansas City Cardiomyopathy Questionnaire total symptom score, and the change of body weight at 24 months.

RESULTS: After matching, 203 patients were included in each group. A primary outcome event occurred in 123 patients (60.6%) in the Sema-Preserved Group and 36 (17.7%) in the Control-Preserved Group (odds ratio: 3.99; 95% confidence interval: 1.69-6.28; p<0.01), and the mean change in body weight was -12.9±4.2kg in patients with semaglutide and -2.5±1.1kg in control patients (p<0.01). There were also significant declines in the heart failure events, and in all-cause hospitalizations.

CONCLUSIONS: Once-weekly 1.00mg semaglutide was associated with improved heart failure health status, and weight loss in patients with heart failure with preserved ejection fraction, obesity, and type 2 diabetes. Further research on glucagon-like peptide-1 receptor agonists in heart failure is needed.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Abstract

Full Text

Related papers